Life Scientist > Biotechnology

Peptide drug could treat long COVID, prevent reinfection

03 July, 2023

A new study shows that the drug prevents inflammation and even repairs damaged lung tissue in preclinical models, making it both a prevention and a treatment.


Stem cell-based regenerative therapy to treat heart failure

30 June, 2023

A new study saw pluripotent (immature) stem cells cultivated in the laboratory to grow into heart muscle precursor cells, which can develop into various types of heart cells.


Needle-free vaccine patch facility opens in Brisbane

26 June, 2023

The custom-built, 5500 m2 Vaxxas Biomedical Facility will support the production of needle-free vaccine patches for future late-stage clinical trials and commercial products.


Selective targeting of cancer cells in new treatment approach

26 June, 2023

Finding a way to make drugs act more selectively on cancer cells is the key to improving treatment success while reducing toxicity in children treated for high-risk leukaemia.


Personalised vaccines trialled for skin cancer treatment

16 June, 2023

An mRNA vaccine tailored to suit an individual's tumour genetics was added to common immunotherapy treatment, with promising results.


UQ partners with US university to create homegrown vaccines

08 June, 2023

The University of Queensland and Emory University have committed to scaling up their collaboration to focus on pandemic preparedness and regional disease prevention.


Oral medication for Crohn's disease approved by FDA

07 June, 2023

Patients with moderate-to-severe Crohn's disease now have a new treatment option to suppress their intestinal inflammation and help them maintain their relief.


Nanoparticle used to deliver brain cancer drug

05 June, 2023

The new silica nanoparticle can be loaded with temozolomide, a small molecule drug used to treat tumours known as glioblastoma.


Sydney Uni spinout lands deal to develop psychiatric drugs

10 May, 2023

Kinoxis Therapeutics has announced a strategic partnership with Boehringer Ingelheim for the development of first-in-class oxytocin-targeting precision psychiatry treatments.


Cognitive decline slowed in Alzheimer's drug trial

08 May, 2023

The phase 3 drug trial from Eli Lilly and Company indicated significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's.


Opportunities for biotech await in the Amazon rainforest

01 May, 2023 by Emily Newton*

As deforestation continues in the Amazon rainforest, humanity could permanently lose an untold number of life-changing drugs.


Micropore Pathfinder for development of RNA/LNP therapeutics and vaccines

01 May, 2023

Harnessing the capabilities of Micropore's AXF mini, together with intuitive software, the AXF Pathfinder is a compact benchtop unit for discovery, development and phase 1 clinical development through to full GMP manufacture of nucleic acid therapeutics and vaccines.


Flexible gold sensor promising for medical implants

27 April, 2023

Researchers have produced a film-like sensor that is both flexible and sensitive enough to enable a more streamlined future for electronic medical implants.


Wireless pacemakers may be safe for children

26 April, 2023

Wireless or leadless pacemakers, commonly implanted in adults, may be a safe and effective short-term option for children with slow heartbeats.


An RNA encapsulation facility in your hand

18 April, 2023

The Micropore AXF (Advanced Cross Flow) range is expected to make a significant contribution to improving the performance of entire nanoparticle manufacturing processes.


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd